Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Brain Biotech AG has 2 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners located in 2 distinct art units. This distribution shows that each pending matter is currently being reviewed by a different examiner within a different unit. The involvement of these 2 distinct art units indicates that the biotechnology filings are categorized into different sub-specialties by the patent office.
DAVID J STEADMAN serves as the busiest examiner for this portfolio, with 1 busiest examiner pending action. This 1 action is part of the 2 pending office actions currently active for the company. Practitioners should note that the 2 distinct examiners may have different prosecution styles, even though they both operate within the Biotechnology & Pharmaceuticals sector.
Managing the portfolio across the 2 distinct art units requires addressing the requirements of each unit simultaneously. The workload is divided, with the busiest examiner managing 1 busiest examiner pending action and the other distinct examiner managing the remaining matter. This arrangement necessitates a strategy that accounts for the examination practices of each unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| §101 + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
| RAMIREZ, DELIA M | 1 | 65.1% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279672 | NOVEL PSEUDOMONAS STRAIN FOR METAL RECOVERY | STEADMAN, DAVID J | — |
| 18548429 | NOVEL CRISPR-CAS NUCLEASES FROM METAGENOMES | RAMIREZ, DELIA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18279672 | NOVEL PSEUDOMONAS STRAIN FOR METAL RECOVERY | STEADMAN, DAVID J | — |
| 18548429 | NOVEL CRISPR-CAS NUCLEASES FROM METAGENOMES | RAMIREZ, DELIA M | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18279672 | NOVEL PSEUDOMONAS STRAIN FOR METAL RECOVERY | STEADMAN, DAVID J | 1656 | §101 | Final Rejection | — | Pending | Aug 31, 2023 |
| 18548429 | NOVEL CRISPR-CAS NUCLEASES FROM METAGENOMES | RAMIREZ, DELIA M | 1652 | §101§112 | Final Rejection | — | Pending | Aug 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBrain Biotech AG has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David J Steadman has the most, with 1 of Brain Biotech AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
